Overview

Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial

Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
0
Participant gender:
All
Summary
Photodynamic therapy (PDT) is a well established treatment option for superficial non melanoma skin cancer, such as superficial basal cell carcinoma (sBCC) and Bowen Disease (BD). However, a limited uptake of the topically applied photosensitizer methyl aminolevulinate (MAL) may reduce its efficacy. Pretreatment with an ablative carbon dioxide (CO2) laser has recently been studied in order to enhance the skin penetration of this photosensitizer. This study compares the results of a full ablative and a fractional ablative CO2 laser mode as pretreatment of PDT in the management of sBCC and BD. The endpoints efficacy, pain, aesthetics and patient preference are investigated during twelve months of follow up.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University Hospital, Ghent
Treatments:
Anesthetics
Anesthetics, Local
Epinephrine
Epinephryl borate
Lidocaine
Methyl 5-aminolevulinate
Racepinephrine
Criteria
Inclusion Criteria: patients with the presence of

- non operable superficial Basal Cell Carcinoma or Bowen's Disease lesions

- and the presence of at least two lesions or the presence of one lesion covering an
area greater than 5cm2

Exclusion Criteria: pregnancy and/or breast feeding